CERT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Certara Inc is not a strong buy for a beginner investor with a long-term strategy at this time. The stock is experiencing a downward trend, with weak financial performance and mixed analyst sentiment. While the company has made strategic moves like selling its regulatory and medical writing business, the financial and technical indicators do not currently support a compelling entry point.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 46.819, and moving averages are converging, showing no clear trend. The stock is trading below its pivot level of 5.982, with key support at 5.577 and resistance at 6.387. Overall, the technical indicators suggest a lack of bullish momentum.
Certara announced the sale of its regulatory and medical writing business to Veristat for up to $135 million, which could allow the company to focus more on its core drug development business.
The stock has seen a significant price decline (-5.96% in regular trading and -1.42% post-market). Analysts have lowered price targets, and there is uncertainty about the company's ability to execute its strategy effectively. Financial performance has been weak, with a significant drop in net income and EPS.
In 2025/Q4, revenue increased by 3.28% YoY to $103.65 million, but net income dropped by -189.63% YoY to -$5.89 million. EPS fell by -200% YoY to -0.04. Gross margin improved slightly to 48.26%, up 0.67% YoY. Overall, the financials indicate weak profitability and growth.
Analysts have mixed views. KeyBanc maintains an Overweight rating with a reduced price target of $8, while UBS and TD Cowen also lowered price targets but maintain Buy ratings. Barclays and Craig-Hallum downgraded the stock, citing concerns about growth and execution. The consensus reflects uncertainty and a lack of strong bullish sentiment.
